Aspira Women's Health Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page hereto)
POWER OF ATTORNEY
Each of the undersigned officers and directors of Aspira Women’s Health Inc., hereby constitutes and appoints Michael Buhle and James Crawford, and each or any of them, as their true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their name to any and all amendments to this Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Michael Buhle | President and Chief Executive Officer | |
| Michael Buhle | (Principal Executive Officer) and Director | March 27, 2025 |
| /s/ James Crawford | Vice President of Finance | |
| James Crawford | (Principal Financial Officer and Principal Accounting Officer) | March 27, 2025 |
| /s/ Jannie Herchuk | Chair of the Board of Directors | March 27, 2025 |
| Jannie Herchuk | ||
| /s/ Ellen Beausang | Director | March 27, 2025 |
| Ellen Beausang | ||
| /s/ Stefanie Cavanaugh | Director | March 27, 2025 |
| Stefanie Cavanaugh | ||
| /s/ Celeste Fralick | Director | March 27, 2025 |
| Celeste Fralick | ||
| /s/ Ellen O’Connor-Vos | Director | March 27, 2025 |
| Ellen O’Connor-Vos | ||
| /s/ Winfred Parnell | Director | March 27, 2025 |
| Winfred Parnell | ||
| /s/ John Ragard | Director | March 27, 2025 |
| John Ragard | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.